Allergan Divests Brazikumab and Zenpep to Move Forward with AbbVie Acquisition

By Michelle Liu

Pharma Deals Review: Vol 2020 Issue 1 (Table of Contents)

Published: 31 Jan-2020

DOI: 10.3833/pdr.v2020.i1.2508     ISSN: 1756-7874

Section: Mergers & Acquisitions



In a move to satisfy regulators, Allergan has agreed to return the rights to inflammatory bowel disease therapy brazikumab to AstraZeneca and divest its gastrointestinal treatment Zenpep® (pancrelipase) to Nestle...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details